Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
Multi-criteria decision framework using acquisition cost, efficacy, organizational impact, administration route, and safety as criteria identifies Selinexor/Bortez/dex as the best option in Italy after relapse from Dara/Rev/dex.”
Title: Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework
Authors: Mario Boccadoro, Angelo Belotti, Felice Bombaci, Sara Bringhen, Gabriele Buda, Anna Maria Cafro, Michele Caimmi, Beatrice Canali, Pier Luigi Canonico, Michele Cavo, Alessandro Corso, Lorenzo De Paoli, Daniele Derudas, Francesco Di Raimondo, Carlotta Galeone, Francesca Gay, Massimo Gentile, Nicola Giuliani, Paola La Malfa, Riccardo Mercati, Vittorio Montefusco, Pellegrino Musto, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci, Massimo Riccaboni, Patrizia Tosi, Elena Zamagni, Renato Zambello, Francesca Fiorentino
You can read the Full Article in BMC Cancer.
You can find more posts featuring Robert Orlowski on OncoDaily.
